Utilization and spending trends for antiretroviral medications in the U.S. Medicaid program from 1991 to 2005

AIDS Research and Therapy

Volumn 4, Issue , 2007, Pages

  Jing, Yonghua ^a   Klein, Patricia ^a   Kelton, Christina M L ^b   Li, Xing ^a   Guo, Jeff J ^a,b  

^a UNIVERSITY OF CINCINNATI MEDICAL CENTER   (United States)

^b UNIVERSITY OF CINCINNATI   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ABACAVIR PLUS LAMIVUDINE; ABACAVIR PLUS LAMIVUDINE PLUS ZIDOVUDINE; AMPRENAVIR; AMPRENAVIR PHOSPHATE; ANTIRETROVIRUS AGENT; ATAZANAVIR; DELAVIRDINE; DIDANOSINE; EFAVIRENZ; EMTRICITABINE; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; ENFUVIRTIDE; INDINAVIR; LAMIVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; LOPINAVIR PLUS RITONAVIR; NELFINAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; TENOFOVIR DISOPROXIL; TIPRANAVIR; UNCLASSIFIED DRUG; VIDEX EC; ZALCITABINE; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; DRUG COST; DRUG MARKETING; DRUG USE; DRUG UTILIZATION; HEALTH CARE FINANCING; HEALTH PROGRAM; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MEDICAID; PRESCRIPTION; PRIORITY JOURNAL; TREND STUDY; UNITED STATES;

EID: 37449027096     PISSN: 17426405     EISSN: None     Source Type: Journal    
DOI: 10.1186/1742-6405-4-22     Document Type: Article

References (27)

1. Centers for Disease Control and Prevention Pneumocystis pneumonia-Los Angeles MMWR 1981, 30:250-252. 6265753
2. The Kaiser Family Foundation Fact sheet: The HIV/AIDS epidemic in the United States http://www.kff.org/hivaids/3029.cfm
3. Centers for Disease Control and Prevention Epidemiology of HIV/ AIDS-United States, 1981-2005 MMWR 2006, 55(21):589-592. 16741494
4. Centers for Disease Control and Prevention HIV/AIDS surveillance report 2004 Atlanta, Georgia 2005. http://www.cdc.gov/hiv/topics/surveillance/ resources/reports/2004report/default.htm
5. Glynn MK Rhodes P Estimated HIV prevalence in the United States at the end of 2003 Presentation National HIV Prevention Conference 2005.
6. National Center for Health Statistics Health, United States 2005
7. Yazdanpanah Y Costs associated with combination antiretroviral therapy in HIV-infected patients J Antimicrob Chemother 2004, 53:558-561. 10.1093/jac/dkh142 14985277
8. Collier AC Coombs RW Schoenfeld DA Bassett RL Timpone J Baruch A Jones M Facey K Whitacre C McAuliffe VJ Friedman HM Merigan TC Reichman RC Hooper C Corey L Treatment of human immunodeficiency virus infection with saquinavir, zidovudine, and zalcitabine N Engl J Med 1996, 334(16):1011-1017. 10.1056/NEJM199604183341602 8598838
9. Cameron DW Heath-Chiozzi M Danner S Cohen C Kravcik S Maurath C Sun E Henry D Rode R Potthoff A Leonard J Randomised placebo-controlled trial of ritonavir in advanced HIV-1 disease Lancet 1998, 351:543-549. 10.1016/ S0140-6736(97)04161-5 9492772
10. Weverling GJ Lange JM Jurriaans S Prins JM Lukashov VV Notermans DW Roos M Schuitemaker H Hoetelmans RM Danner SA Goudsmit J de Wolf F Alternative multidrug regimen provides improved suppression of HIV-1 replication over triple therapy AIDS 1998, 12:F117-F122. 10.1097/ 00002030-199811000-00003 9708401
11. Hoyert DL Heron MP Murphy SL Kung HC Deaths: Final data for 2003 Natl Vital Stat Rep 2006, 54(13):1-120. 16689256
12. Coombs RW Welles SL Hooper C Reichelderfer PS D'Aquila RT Japour AJ Johnson VA Kuritzkes DR Richman DD Kwok S Todd J Jackson JB DeGruttola V Crumpacker CS Kahn J Association of plasma human immunodeficiency virus type 1 RNA level with risk of clinical progression in patients with advanced infection. AIDS Clinical Trials Group (ACTG) 116B/117 Study Team. ACTG Virology Committee Resistance and HIV-1 RNA Working Groups J Infect Dis 1996, 174(4):704-712. 8843206
13. Katzenstein DA Hammer SM Hughes MD Gundacker H Jackson JB Fiscus S Rasheed S Elbeik T Reichman R Japour A Merigan TC Hirsch MS The relation of virologic and immunologic markers to clinical outcomes after nucleoside therapy in HIV-1 infected adults N Engl J Med 1996, 335:1091-1098. 10.1056/NEJM199610103351502 8813039
14. Cascade Collaboration Survival after introduction of HAART in people with known duration of HIV-1 infection Lancet 2000, 355:1158-1159. 10.1016/S0140-6736(00)02069-9 10791383
15. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents http://www.aidsinfo.nih.gov/Guidelines/ GuidelineDetail.aspx?MenuItem=Guidelines&Search=Off&GuidelineID= 7&ClassID=1 October 10, 2006
16. Food And Drug Administration http://www.accessdata.fda.gov/scripts/cder/ drugsatfda/
17. Food and Drug Administration Expanded access and expedited approval of new therapies related to HIV/AIDS http://www.fda.gov/oashi/aids/ expanded.html
18. Nature reviews drug discovery, 2003 approvals: A year of innovation and upward trends Nature 2004, 3:103-105. http://www.nature.com/drugdisc/ news/articles/boxes/nrd1327_bx1.html 10.1038/nmat1058
19. Centers for Medicare & Medicaid Services Medicaid drug rebate program overview http://www.cms.hhs.gov/MedicaidDrugRebateProgram
20. Bozzette SA Joyce G McCaffrey DF Leibowitz AA Morton SC Berry SH Rastegar A Timberlake D Shapiro MF Goldman DP HIV Cost and Services Utilization Study Consortium HIV Cost and Services Utilization Study Consortium. Expenditures for the care of HIV-infected patients in the era of highly active antiretroviral therapy N Engl J Med 2001, 344(11):817-823. 10.1056/NEJM200103153441107 11248159
21. Shapiro MF Morton SC McCaffrey DF Senterfitt JW Fleishman JA Perlman JF Athey LA Keesey JW Goldman DP Berry SH Bozzette SA Variations in the care of HIV-infected adults in the United States: Results from the HIV Cost and Services Utilization Study JAMA 1999, 281(24):2305-2315. 10.1001/jama.281.24.2305 10386555
22. Kahn JG Zhang X Cross LT Palacio H Birkhead GS Morin SF Access to and use of HIV antiretroviral therapy: Variation by race/ethnicity in two public insurance programs in the U.S Public Health Reports 2002, 117(3):252-262. discussion 231-232 1497435 12432136
23. Sambamoorthi U Collins S Crystal S Dually eligible individuals with AIDS: Characteristics and health services use J Health Soc Policy 2001, 14(1):19-35. 10.1300/J045v14n01_02 11374296
24. Hammer SM Squires KE Hughes MD Grimes JM Demeter LM Currier JS Eron JJ Jr Feinberg JE Balfour HH Jr Deyton LR Chodakewitz JA Fischl MA A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less N Engl J Med 1997, 337(11):725-733. 10.1056/ NEJM199709113371101 9287227
25. The Kaiser Family Foundation Medicaid at a glance http://www.kff.org/ medicaid/7235.cfm
26. An overview of AIDS drug access in the United States http://www.thebody.com/iapac/may04_suppl/overview.html
27. Centers for Medicare & Medicaid Services State drug utilization data http://www.cms.hhs.gov/MedicaidDrugRebateProgram/SDUD/list.asp#TopOfPage